atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus pemetrexed and platin
pembrolizumab and pemetrexed plus platin
pembrolizumab plus SoC
non squamous - mNSCLC - L1 - Wild Type (WT) 6
Comparator:
vs bevacizumab plus carboplatin and paclitaxel; vs carboplatin plus nab-paclitaxel; vs pemetrexed plus platin; vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;